-
公开(公告)号：KR101347734B1
公开(公告)日：2014-01-14
申请号：KR1020120027117
申请日：2012-03-16
Applicant: 한림대학교 산학협력단
Abstract: 파킨슨병은 뇌의 흑색질 내에서 도파민 뉴런이 점차 상실되는 신경퇴행성 질환이다. 리보솜 단백질 S3 (rpS3)는 단백질 합성, 항산화 및 UV 엔도뉴클리에이즈 Ⅲ 활성과 같은 다양한 기능을 수행한다. 본 발명자들은 앞선 연구에서 PEP-1-rpS3 융합단백질이 피부염증을 억제하고 뇌허혈 손상에서 신경보호효과를 나타냄을 밝혔다. 본 발명자들은 PEP-1-rpS3 융합단백질이 SH-SY5Y 신경아세포종 세포 및 파킨슨병 동물모델에서 산화 스트레스로부터 도파민 뉴런을 보호할 수 있음을 밝혀내었다. PEP-1-rpS3 융합단백질은 SH-SY5Y 세포 내로 그리고 뇌의 흑색질 내로 잘 이동함을 웨스턴 블랏 분석으로 확인하였다. PEP-1-rpS3 융합단백질은 MPP
+ 로 유도되는 활성산소종 생성 및 DNA 조각화를 현저히 저해하였으며, 결과적으로 SH-SY5Y 세포의 생존을 유도했다. 신경보호 효과는 PEP-1-rpS3 융합단백질이 친-자기세로사멸 매개자 및 항-자기세포사멸 매개자의 수준에 영향을 미침으로써 얻어진다. 나아가, TH 항체 및 크레실 바이올렛 염색을 이용한 면역조직화학 분석 데이타는 PEP-1-rpS3 융합단백질이 MPTP와 같은 산화 스트레스에 대하여 흑색질 내의 도파민 세포를 현저히 보호함을 나타낸다. 따라서, PEP-1-rpS3 융합단백질은 파킨슨병의 예방 및 치료 용도로 이용 가능하다.-
公开(公告)号：KR1020130105775A
公开(公告)日：2013-09-26
申请号：KR1020120027117
申请日：2012-03-16
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/17 , C07K14/435 , C12N15/62
Abstract: PURPOSE: A pharmaceutical composition containing PEP1-1-rpS3 fusion proteins for preventing and treating Parkinson's disease is provided to remarkably protect dopaminergic cells of substantia nigra from oxidative stresses such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). CONSTITUTION: A pharmaceutical composition for preventing and treating Parkinson's disease contains rpS fusion proteins which are prepared by covalent bond of a protein transport domain at N-terminal and/or C-terminal of rpS protein. The protein transport domain is selected among: a protein transport domain comprising a hydrophobic domain which consists of 15-30 amino acids containing 5 or more tryptophan, hydrophilic domains with four or more lysine, and a spacer which separates two domains; an oligolysine protein transport domain which consists of 6-12 lysine; an oligoarginine protein transport domain which consists of 56-12 arginine; and oligo (lysine, arginine) protein transport domain which consists of 6-12 lysine or arginine.
Abstract translation: 目的：提供含有用于预防和治疗帕金森病的PEP1-1-rpS3融合蛋白的药物组合物，以显着保护黑质的多巴胺能细胞免受氧化应激，如1-甲基-4-苯基-1,2,3,6-四氢 - 四氢吡啶（MPTP）。 构成：用于预防和治疗帕金森病的药物组合物含有rpS融合蛋白，其通过rpS蛋白的N末端和/或C末端的蛋白质转运结构域的共价键制备。 蛋白质转运结构域选自：包含疏水结构域的蛋白质转运结构域，其由含有5个或更多个色氨酸的15-30个氨基酸组成，具有四个或更多赖氨酸的亲水结构域和分离两个结构域的间隔基; 由6-12赖氨酸组成的寡聚赖氨酸蛋白转运结构域; 由精氨酸56-12组成的寡精氨酸蛋白转运结构域; 和由6-12赖氨酸或精氨酸组成的寡聚（赖氨酸，精氨酸）蛋白质转运结构域。
-
Patent Agency Ranking
公开(公告)号：KR1020160011257A
公开(公告)日：2016-02-01
申请号：KR1020140091711
申请日：2014-07-21
Applicant: 한림대학교 산학협력단
Abstract: 본발명은 GADD45a 융합단백질을포함하는피부암예방및 치료용약학조성물에관한것으로서, 단백질수송도메인과공유결합된 GADD45a 융합단백질은세포에효과적으로침투하여, UV로유도된암의수와크기를현저히감소시키는것으로나타나 GADD45a 융합단백질은피부암의예방및 치료용도로이용가능하다.
Abstract translation: 本发明涉及包含用于预防和治疗皮肤癌的GADD45a融合蛋白的药物组合物。 共价键合到蛋白质转运结构域的GADD45a融合蛋白通过有效地穿透细胞可以显着减少癌细胞的大小和数量。 因此，GADD45a融合蛋白可用于预防和治疗皮肤癌。
-
公开(公告)号：KR1020150114107A
公开(公告)日：2015-10-12
申请号：KR1020140037927
申请日：2014-03-31
Applicant: 한림대학교 산학협력단
Abstract: 본발명자들은 PEP-1-PON1 융합단백질이 SH-SY5Y 신경아세포종세포및 파킨슨병동물모델에서산화스트레스로부터도파민뉴런을보호할수 있음을밝혀내었다. PEP-1-PON1융합단백질은 SH-SY5Y 세포내로그리고뇌의흑색질내로잘 이동함을웨스턴블랏분석으로확인하였다. PEP-1-PON1 융합단백질은 MPP로유도되는활성산소종생성및 DNA 단편화를현저히저해하였으며, 결과적으로 SH-SY5Y 세포의생존을유도했다. 신경보호효과는 PEP-1-PON1 융합단백질이친-자기세로사멸매개자및 항-자기세포사멸매개자의수준에영향을미침으로써얻어진다. 나아가, TH 항체및 크레실바이올렛염색을이용한면역조직화학분석데이타는 PEP-1-PON1 융합단백질이 MPTP와같은산화스트레스에대하여흑색질내의도파민세포를현저히보호함을나타낸다. 따라서, PEP-1-PON1 융합단백질은파킨슨병의예방및 치료용도로이용가능하다.
Abstract translation: 本发明人发现PEP-1-PON1融合蛋白可以保护多巴胺能神经元免受SH-SY5Y神经母细胞瘤细胞和帕金森病动物模型中的氧化应激。 证实PEP-1-PON1融合蛋白能够容易地进入SH-SY5Y神经母细胞瘤细胞和黑质黑质。 PEP-1-PON1融合蛋白可以显着抑制由MPP +和DNA断裂引起的活性氧的产生，从而诱导SH-SY5Y细胞的存活。 PEP-1-PON1融合蛋白影响促凋亡介质和抗自身凋亡介质的水平，以获得神经保护作用。 此外，TH抗体和使用甲酚紫染料的免疫组织化学分析数据显示，PEP-1-PON1融合蛋白可以显着保护黑质中的多巴胺细胞免受氧化酶如MPTP的影响。 因此，PEP-1-PON1融合蛋白可用于预防和治疗帕金森病。
-
公开(公告)号：KR1020140108411A
公开(公告)日：2014-09-11
申请号：KR1020130020953
申请日：2013-02-27
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/08 , A61K38/10 , A61K38/16 , C07K7/06 , C07K7/08 , C07K14/00 , C12N15/62
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory arthritis, and more specifically, to a pharmaceutical composition for preventing or treating inflammatory arthritis containing fusion protein of FK506 binding protein which can go through the inside of cartilaginous tissue as an active ingredient.
Abstract translation: 本发明涉及用于预防或治疗炎症性关节炎的药物组合物，更具体地说，涉及一种用于预防或治疗含有可通过软骨组织内作为活性成分的FK506结合蛋白的融合蛋白的炎症性关节炎药物组合物。
-
公开(公告)号：KR1020130134530A
公开(公告)日：2013-12-10
申请号：KR1020120058107
申请日：2012-05-31
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/177 , Y10S530/839
Abstract: Phosphoprotein enriched in astrocytes-15 (PEA-15) is a small protein created in neurons or astrocytic cells in brain. This protein which is a multi-functional protein can increase the cell survival rate thanks to its antiapoptotic and proapoptotic properties. Parkinson's disease is a neurodegenerative disease that dopamine neurons are reduced in substantia nigra in brain. The inventers found out that PEP-1-PEA-15 fusion protein can protect dopamine neurons from oxidation stress in SH-SY5Y neuroblastom cells and animals suffering from Parkinson's disease. It is confirmed that PEP-1-PEA-15 fusion protein can be transferred to SH-SY5Y cells and substantia nigra through western blot analysis. PEP-1-PEA-15 fusion protein prevents the active oxygen species production DNA tessellation induced to MPP+ and induces SH-SY5Y cell survival. Transmitted PEP-1-PEA-15 fusion protein improves the expression level of Bcl-2 protein but reduces the impression level of Bax protein. Also, PEP-1-PEA-15 fusion protein is transmitted to substantia nigra and prevents dopamine neuron cell death in substantia nigra. Therefore, PEP-1-PEA-15 fusion protein can prevent and treat Parkinson's disease.
Abstract translation: 富含星形胶质细胞-15（PEA-15）的磷酸蛋白是在脑中神经元或星形细胞细胞中产生的小蛋白质。 作为多功能蛋白质的蛋白质可以通过其抗细胞凋亡和促凋亡性质而增加细胞存活率。 帕金森病是神经退行性疾病，多巴胺神经元在脑黑质中减少。 发明人发现PEP-1-PEA-15融合蛋白可以保护多巴胺神经元免受SH-SY5Y神经母细胞和帕金森病动物的氧化应激。 证实通过western印迹分析可以将PEP-1-PEA-15融合蛋白转移至SH-SY5Y细胞和黑质。 PEP-1-PEA-15融合蛋白可阻止活性氧生成诱导MPP +的DNA镶嵌，诱导SH-SY5Y细胞存活。 转染的PEP-1-PEA-15融合蛋白提高了Bcl-2蛋白的表达水平，降低了Bax蛋白的印象。 此外，PEP-1-PEA-15融合蛋白传播到黑质，并防止黑质中的多巴胺神经元细胞死亡。 因此，PEP-1-PEA-15融合蛋白可以预防和治疗帕金森病。
-
公开(公告)号：KR1020120035566A
公开(公告)日：2012-04-16
申请号：KR1020100097161
申请日：2010-10-06
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/1709 , C07K14/47 , C12N15/62 , Y10S514/824
Abstract: PURPOSE: A pharmaceutical composition containing cell permeable rpS3 fusion protein is provided to smoothly deliver rpS3 fusion proteins into neural cells and to prevent the neural cells from apoptosis. CONSTITUTION: A pharmaceutical composition for preventing and treating neural diseases contains a cell permeable rpS3 fusion protein having a protein transduction domain linked to at least one end among N-terminal and C-terminal of rpS3 protein by covalent bond. The protein transduction domain comprises: a non-hydrophilic domain containing 15-30 amino acids and 5 or more tryptophans; a hydrophilic domain containing 4 or more lysines; and a spacer which separates two domains the rpS3 fusion protein has an amino acid sequence of sequence number 7, 9, or 11.
Abstract translation: 目的：提供含有细胞渗透性rpS3融合蛋白的药物组合物，以将rpS3融合蛋白顺利递送至神经细胞，并防止神经细胞凋亡。 构成：用于预防和治疗神经疾病的药物组合物含有通过共价键在rpS3蛋白的N末端和C末端连接至少一端的蛋白转导结构域的细胞可渗透的rpS3融合蛋白。 蛋白质转导结构域包含：含有15-30个氨基酸和5个或更多个色氨酸的非亲水结构域; 含有4个或更多赖氨酸的亲水结构域; 和分离两个结构域的间隔区，rpS3融合蛋白具有序列号7,9或11的氨基酸序列。
-
-
-
-
-
-
Search Results
7
records
(took 0.024 seconds)
